Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We compared several tetracycline and toyocamycin-induci...

Full description

Bibliographic Details
Main Authors: Reetta A. E. Eriksson, Tiina Nieminen, Lionel Galibert, Sanna K. Peltola, Petra Tikkanen, Piia Käyhty, Hanna M. Leinonen, Igor Oruetxebarria, Saana Lepola, Anniina J. Valkama, Eevi M. Lipponen, Hanna P. Lesch, Seppo Ylä-Herttuala, Kari J. Airenne
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Medicine
Subjects:
riboswitch
ON-switch
gene therapy
AAV (adeno-associated virus)
VEGF-B
tetracycline
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1052318/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1052318/full

Similar Items